Sarepta Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Financial Results. Also, Cantor Fitzgerald Upgraded the Stock From Neutral to Overweight and Raided Its Price Target From $152 to $167.
Sarepta Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Financial Results. Also, Cantor Fitzgerald Upgraded the Stock From Neutral to Overweight and Raided Its Price Target From $152 to $167.
sarepta therapeutics股價上漲，公司發佈了好於預期的第三季度財務業績。此外，康泰爾菲茨傑拉德將股票評級從中立調升至超配，並將目標股價從152美元提高到167美元。
Sarepta Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Financial Results. Also, Cantor Fitzgerald Upgraded the Stock From Neutral to Overweight and Raided Its Price Target From $152 to $167.
sarepta therapeutics股價上漲，公司發佈了好於預期的第三季度財務業績。此外，康泰爾菲茨傑拉德將股票評級從中立調升至超配，並將目標股價從152美元提高到167美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間